Document Detail


The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
MedLine Citation:
PMID:  11967819     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The RENAAL Study is a double-blind, placebo-controlled trial to evaluate the renal protective effects of losartan in Type 2 diabetic patients with nephropathy. The study has enrolled 1513 patients and is expected to continue for 3.5 years after the last patient has been entered. Eligible patients must have a urinary albumin:creatinine ratio of at least 300 mg/g and serum creatinine between 1.3 to 3.0 mg/dL. Eligible hypertensive or normotensive patients are randomised to receive either losartan or placebo, in addition to their existing antihypertensive therapy. Medications that block angiotensin production or action, are excluded. The primary endpoint is a composite of the time to first event of doubling of serum creatinine, end-stage renal disease, or death; secondary endpoints include cardiovascular events, progression of renal disease, and changes in proteinuria; tertiary endpoints include quality of life, healthcare resource utilisation, and amputations. Patients include Caucasians (48.6%), Blacks (15.2%), Asians (16.7%), and Hispanics (18.2%). Baseline urinary albumin:creatinine ratio and serum creatinine levels average 1867 mg/g and 1.9 mg/dL, respectively. Mean systolic and diastolic blood pressures are 153 and 82 mmHg, respectively. RENAAL will document whether blockade of the AII receptor with losartan produces clinical benefits in patients with Type 2 diabetes and nephropathy.
Authors:
B M Brenner; M E Cooper; D de Zeeuw; J P Grunfeld; W F Keane; K Kurokawa; J B McGill; W E Mitch; H H Parving; G Remuzzi; A B Ribeiro; M D Schluchter; D Snavely; Z Zhang; R Simpson; D Ramjit; S Shahinfar;
Related Documents :
21073619 - Prevalence of respiratory symptoms in patients with achalasia.
21507679 - Resolution of hydronephrosis after uterine artery embolization for fibroids.
21360469 - A pilot study of routine colloid infusion in hypotension-prone dialysis patients unresp...
2222019 - Ionized calcium, parathormone, and mortality in critically ill surgical patients.
21552179 - Accommodative functions with multifocal contact lenses: a pilot study.
21211789 - Identification of periodontal pathogens and severity of periodontitis in patients with ...
7956389 - Effect of posture on bronchial reactivity to inhaled methacholine in patients with mitr...
2125129 - Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bip...
22106349 - Rapid needle-out patient-rollover time after percutaneous ct-guided transthoracic biops...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of the renin-angiotensin-aldosterone system : JRAAS     Volume:  1     ISSN:  1470-3203     ISO Abbreviation:  J Renin Angiotensin Aldosterone Syst     Publication Date:  2000 Dec 
Date Detail:
Created Date:  2002-04-22     Completed Date:  2002-06-06     Revised Date:  2005-12-23    
Medline Journal Info:
Nlm Unique ID:  100971636     Medline TA:  J Renin Angiotensin Aldosterone Syst     Country:  England    
Other Details:
Languages:  eng     Pagination:  328-35     Citation Subset:  IM    
Affiliation:
Renal Division, Brigham and Women's Hospital, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / drug therapy*
Double-Blind Method
Female
Humans
Losartan / therapeutic use*
Male
Middle Aged
Receptors, Angiotensin / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Receptors, Angiotensin; 114798-26-4/Losartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Practical implications of current natriuretic peptide research.
Next Document:  The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in ...